De la Fouchardière et al. [23] saw hypertension (50%), diarrhea (86%), and AST/ALT increase (44%) as common side effects, with 54% of patients experiencing grade 3–4 adverse events before randomization. The gene discussed is GPT; the disease is hypertensive disorder.